Last updated: April 26, 2026
What is hydroxyprogesterone caproate’s current clinical and regulatory status?
Hydroxyprogesterone caproate (HPC), used to reduce recurrent preterm birth in women with a prior spontaneous preterm birth, lost regulatory support in the U.S. after evidence showed lack of efficacy in confirmatory data. The U.S. regulatory shift has directly reduced commercial viability and has changed the clinical-trial landscape toward either (1) discontinued registrational efforts, (2) smaller studies with alternative endpoints or subpopulations, or (3) non-U.S. development.
Key U.S. action
- FDA withdrew approval for Makena (hydroxyprogesterone caproate) and implemented a phase-out of marketing in the U.S. based on confirmatory trial results and the agency’s benefit-risk determination. FDA later communicated that compounded versions are also subject to enforcement considerations. (FDA communications and withdrawal decision; see sources [1], [2].)
- Confirmatory evidence basis: FDA’s decision cites the PROLONG trial findings, which did not confirm benefit for the primary clinical endpoint in the intended population. (FDA; see sources [1], [3].)
Registrational study context
- PROLONG (confirmatory) is the central dataset FDA used to determine the lack of clinically meaningful reduction in recurrent preterm birth compared with placebo. (PROLONG publication; see sources [3].)
- Earlier randomized data supporting approval relied on smaller studies with different study design and baseline population characteristics, which did not translate into confirmatory efficacy. (FDA decision; see sources [1].)
What clinical-trial activity remains material?
Because FDA withdrew the U.S. indication and marketing authorization, ongoing global clinical work is generally limited in scope and primarily targeted at:
- alternative formulations or regimens intended to overcome exposure or adherence variability,
- different risk strata or endpoints (including obstetric safety endpoints),
- non-U.S. regulatory strategies where the label may differ or where local authorities permit distinct evidence thresholds.
Operational takeaway for pipeline tracking
- For business planning, the credible signal is not “new phase progression” in the U.S. but whether any developer is pursuing a product that can pass label expansion or re-authorization in jurisdictions that have not followed the same evidentiary interpretation as the FDA.
What is the competitive market structure for HPC today?
After FDA withdrawal of Makena’s approval, HPC’s market became fragmented between:
- residual, time-bound availability (where any supply existed at withdrawal),
- imported or localized products outside the U.S. (depending on local approvals),
- compounded access (subject to regulatory scrutiny),
- replacement with other prevention strategies and competitor products used for preterm birth prevention in the U.S. and other markets.
Therapeutic substitution pressure
- HPC has faced substitution from other progesterone-based strategies, including vaginal progesterone (in selected populations) and 17P alternatives in some markets (with market access and guidelines varying by country and professional society). FDA’s withdrawal changes the prescribing baseline in the U.S. (FDA; see sources [1], [2].)
Brand reference point
- Makena is the primary U.S. brand reference for HPC. Its withdrawal altered pricing power and demand stability for any remaining HPC channel. (FDA; see sources [1].)
How big is the addressable market post-withdrawal?
U.S.
The post-withdrawal U.S. market is not a normal “continuing sales” market; it is a wind-down and constrained access environment. The dominant determinant of future volume is regulatory permissibility, clinician willingness, and substitution adoption, not typical demand growth.
Market drivers
- FDA’s decision to withdraw approval reduces the number of prescribers acting on label-conforming indications.
- Residual use depends on:
- local state policies on compounded products and enforcement discretion,
- payer reimbursement behavior post-withdrawal,
- clinical guideline updates reflecting the U.S. evidence interpretation.
Regulatory constraint point
- FDA communications explicitly tie the withdrawal to benefit-risk reassessment and phase-out expectations for Makena, reducing commercial runway in the U.S. (FDA; see sources [1], [2].)
Non-U.S.
Non-U.S. opportunity depends on:
- local regulatory status of HPC,
- whether local authorities still support progesterone therapy for prevention of recurrent preterm birth based on local review of evidence,
- whether alternative progesterone strategies are preferred in guideline ecosystems.
Practical projection approach
- Non-U.S. remains the only credible geography for volume persistence.
- However, global “addressable” size must be discounted because the FDA action has reduced global confidence, which typically accelerates guideline updates and tender decisions even where formal label withdrawal has not occurred.
What are the market projections for hydroxyprogesterone caproate (2025-2030)?
Given the FDA withdrawal and the resulting U.S. wind-down, projection should be treated as an industry supply-and-access model rather than a standard growth forecast.
Projection framework (what to model)
- U.S.: near-zero sustainable growth; volumes track residual access and substitution.
- International: modest decline or flat-to-down volumes depending on local label persistence and payer adoption of alternatives.
- Channel constraints: supply continuity, reimbursement access, and compounded availability variability.
Base-case forecast (scenario method anchored to U.S. policy shock)
Base-case thesis
- U.S. sales of approved HPC products remain effectively discontinued after the withdrawal timeline; any remaining HPC demand is limited and policy-dependent.
- International volume declines gradually as guidelines follow U.S. evidence interpretation and payers tighten controls.
Indicative forecast (index model)
- 2025: 0.10x to 0.20x of the pre-withdrawal U.S. peak annual demand level; international at 0.60x to 0.80x of pre-withdrawal international demand.
- 2027: U.S. at 0.05x to 0.10x; international at 0.50x to 0.70x.
- 2030: U.S. at 0.02x to 0.05x; international at 0.40x to 0.60x.
This yields a combined (U.S. + international) trajectory that trends down through 2030.
Why this direction fits the evidence record
- FDA’s withdrawal is the single biggest exogenous shock to demand in the largest clinical guideline ecosystem, and it is anchored in confirmatory trial results rather than adoption-only friction. (FDA; PROLONG; see sources [1], [3].)
Revenue projection implications for investors
- If a developer continues HPC product life-cycle management, the realistic revenue path is:
- low growth,
- margin pressure from supply constraints and competitive substitution,
- high regulatory risk for any new indication efforts in the U.S.
- Investment decisions should treat HPC as a “residual-market” product class, unless a new formulation/regimen can generate evidence strong enough to overcome the FDA’s benefit-risk position.
What is the clinical evidence that drove the market reset?
Confirmatory efficacy failure
- The FDA’s withdrawal decision cites lack of confirmed benefit in the confirmatory study (PROLONG). (FDA; see sources [1].)
- PROLONG reported no significant reduction in the primary outcome versus placebo in the intended population. (PROLONG publication; see sources [3].)
Consequence for label and demand
- A label removal in the U.S. typically triggers:
- payer reimbursement withdrawal or restrictions,
- guideline re-alignment,
- reduced clinical trial recruitment and reduced sponsor appetite for large confirmatory programs.
What new studies could still matter commercially?
Commercially relevant studies would need to do at least one of the following:
- demonstrate efficacy in a clearly defined subgroup or with a different endpoint that regulators treat as clinically meaningful,
- show a differentiated safety profile versus alternatives,
- address pharmacokinetic exposure consistency and demonstrate comparable or improved clinical benefit.
In practice, given FDA’s evidentiary position, the threshold for “commercially investable proof” is high.
What should companies assume about competitive dynamics?
Substitution and guideline adherence
- In the U.S., clinicians align with FDA labeling and guideline consensus, which reduces the “conversion” of progesterone-prevention demand to HPC.
- Alternatives such as vaginal progesterone remain more commonly used depending on patient risk profile and guideline updates. (FDA action and PROLONG influence; see sources [1], [3].)
Buyer behavior
- Health systems and payers typically treat HPC as a low-priority procurement after withdrawal.
- Any remaining buyers are likely to be driven by:
- availability,
- prescribing inertia,
- compounded or off-label access governed by local policy.
Quantitative snapshot: key dates and decision points
| Event |
Date |
Impact on market and clinical development |
| FDA withdrew approval for Makena |
2023 (FDA action; timeline communications) |
Eliminates approved U.S. sales trajectory for HPC; triggers phase-out and reduces prescribing for label-based use. (FDA; [1], [2]) |
| FDA cited confirmatory lack of benefit (PROLONG) |
Decision basis in withdrawal |
Converts evidence from “supportive but unconfirmed” to “not confirmed,” shrinking investable U.S. pathway. (FDA; [1], [3]) |
| PROLONG confirmatory trial result published |
2019 |
Central efficacy failure supporting withdrawal decision. (PROLONG; [3]) |
Key takeaways
- Hydroxyprogesterone caproate’s U.S. market is structurally constrained by FDA withdrawal tied to confirmatory lack of efficacy in PROLONG. (FDA; [1], [3].)
- The clinical trial landscape is unlikely to produce near-term U.S. registrational re-entry without new, high-quality evidence that directly addresses the failure mode seen in confirmatory data.
- Market projection through 2030 should assume residual access in the U.S. and a slow international decline driven by guideline and payer substitution, with any growth requiring a differentiated, regulator-accepted clinical package.
FAQs
1) Is hydroxyprogesterone caproate still approved in the U.S. for preventing recurrent preterm birth?
No. FDA withdrew approval for Makena and directed phase-out consistent with the benefit-risk reassessment based on confirmatory evidence. (FDA; [1], [2].)
2) Which trial most directly influenced FDA’s decision?
The confirmatory PROLONG trial, which did not demonstrate the expected benefit for the primary clinical endpoint versus placebo in the intended population. (FDA; [1], [3].)
3) What does the market shift imply for new HPC development investment in the U.S.?
U.S. investment economics become dependent on overcoming the FDA’s evidentiary conclusions, which raises the evidentiary bar for any new regimen or formulation. (FDA; [1].)
4) Does hydroxyprogesterone caproate have a meaningful non-U.S. market?
Non-U.S. demand depends on local regulatory status and guideline adoption. The FDA decision typically pressures international adoption even where formal withdrawal has not occurred, supporting an overall downtrend assumption. (FDA; [1].)
5) What is the most likely demand driver post-withdrawal?
Residual access patterns (policy-dependent), substitution by other preventive strategies, and remaining international label persistence rather than standard demand growth dynamics. (FDA; [1], [3].)
References
[1] U.S. Food and Drug Administration. (2023). FDA requests withdrawal of 17P (hydroxyprogesterone caproate) from the market. https://www.fda.gov/
[2] U.S. Food and Drug Administration. (2023). FDA communication on compounding and access related to hydroxyprogesterone caproate (17P). https://www.fda.gov/
[3] Blackwell, S. C., et al. (2019). Hydroxyprogesterone caproate to prevent recurrent preterm birth. The New England Journal of Medicine. https://www.nejm.org/
